Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, PRECISION BIOSCIENCES INC reported revenue of $34M, down 50.1% year over year. Operating margin was -152.2% and net margin -133.4%, on a free-cash-flow margin of -192.4% with capital expenditure at 0.2% of revenue. Every figure is computed directly from DTIL's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $34M | -152.2% | -133.4% |
| FY2024 | $69M | -38.1% | 10.4% |
| FY2023 | $49M | -89.8% | -125.8% |
| FY2022 | $25M | -248.3% | -444.8% |
| FY2021 | $116M | -34.1% | -26.5% |
How does DTIL compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.